Media coverage about Heska (NASDAQ:HSKA) has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Heska earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 46.8371015842003 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the news headlines that may have impacted Accern’s rankings:

HSKA has been the topic of several research analyst reports. Aegis reissued a “buy” rating on shares of Heska in a research note on Tuesday, December 19th. Zacks Investment Research lowered shares of Heska from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. BidaskClub lowered shares of Heska from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. B. Riley set a $93.00 price objective on shares of Heska and gave the company a “hold” rating in a research report on Monday, February 26th. Finally, Sidoti upgraded shares of Heska from a “neutral” rating to a “buy” rating and set a $94.00 price objective for the company in a research report on Monday, February 5th. Three analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $104.08.

Heska (NASDAQ:HSKA) traded up $2.39 during trading hours on Friday, hitting $66.87. 100,365 shares of the stock traded hands, compared to its average volume of 161,719. Heska has a one year low of $56.59 and a one year high of $115.00. The company has a market cap of $467.08, a price-to-earnings ratio of 51.05, a price-to-earnings-growth ratio of 1.67 and a beta of 0.82.

Heska (NASDAQ:HSKA) last posted its quarterly earnings data on Wednesday, February 28th. The medical research company reported $0.63 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.07. Heska had a net margin of 7.53% and a return on equity of 16.23%. The company had revenue of $36.04 million during the quarter, compared to analyst estimates of $40.56 million. During the same quarter last year, the firm posted $0.46 EPS. The business’s revenue for the quarter was down 8.8% on a year-over-year basis. equities analysts forecast that Heska will post 2.09 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at

Heska Company Profile

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Insider Buying and Selling by Quarter for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with's FREE daily email newsletter.